Tags

Type your tag names separated by a space and hit enter

Quantification of the nail fold capillary abnormalities in systemic sclerosis and Raynaud's syndrome.
Acta Derm Venereol. 1986; 66(2):139-43.AD

Abstract

Measurements were made of capillary luminal diameters and capillary numbers in four groups: 19 normal controls 10 patients with 'idiopathic' Raynaud's disease, 12 patients with Raynaud's phenomenon with an underlying connective tissue disease other than systemic sclerosis, and 18 patients with systemic sclerosis. There was a significant reduction of capillary numbers in all three patient groups compared with the normal controls. Both the afferent and efferent luminal diameters were also increased in each patient group. Patients with Raynaud's phenomenon, either on its own or associated with connective tissue disease, gave results intermediate between normal controls and patients with systemic sclerosis. There were no significant correlations between either the reduction in capillary numbers or increase in luminal diameter with disease severity or duration in systemic sclerosis. It is unlikely that capillary microscopy will provide useful prognostic information for an individual patient with systemic sclerosis; its predictive value in Raynaud's disease must await the outcome of long term follow-up studies.

Authors

No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

2424237

Citation

Statham, B N., and N R. Rowell. "Quantification of the Nail Fold Capillary Abnormalities in Systemic Sclerosis and Raynaud's Syndrome." Acta Dermato-venereologica, vol. 66, no. 2, 1986, pp. 139-43.
Statham BN, Rowell NR. Quantification of the nail fold capillary abnormalities in systemic sclerosis and Raynaud's syndrome. Acta Derm Venereol. 1986;66(2):139-43.
Statham, B. N., & Rowell, N. R. (1986). Quantification of the nail fold capillary abnormalities in systemic sclerosis and Raynaud's syndrome. Acta Dermato-venereologica, 66(2), 139-43.
Statham BN, Rowell NR. Quantification of the Nail Fold Capillary Abnormalities in Systemic Sclerosis and Raynaud's Syndrome. Acta Derm Venereol. 1986;66(2):139-43. PubMed PMID: 2424237.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Quantification of the nail fold capillary abnormalities in systemic sclerosis and Raynaud's syndrome. AU - Statham,B N, AU - Rowell,N R, PY - 1986/1/1/pubmed PY - 1986/1/1/medline PY - 1986/1/1/entrez SP - 139 EP - 43 JF - Acta dermato-venereologica JO - Acta Derm. Venereol. VL - 66 IS - 2 N2 - Measurements were made of capillary luminal diameters and capillary numbers in four groups: 19 normal controls 10 patients with 'idiopathic' Raynaud's disease, 12 patients with Raynaud's phenomenon with an underlying connective tissue disease other than systemic sclerosis, and 18 patients with systemic sclerosis. There was a significant reduction of capillary numbers in all three patient groups compared with the normal controls. Both the afferent and efferent luminal diameters were also increased in each patient group. Patients with Raynaud's phenomenon, either on its own or associated with connective tissue disease, gave results intermediate between normal controls and patients with systemic sclerosis. There were no significant correlations between either the reduction in capillary numbers or increase in luminal diameter with disease severity or duration in systemic sclerosis. It is unlikely that capillary microscopy will provide useful prognostic information for an individual patient with systemic sclerosis; its predictive value in Raynaud's disease must await the outcome of long term follow-up studies. SN - 0001-5555 UR - https://www.unboundmedicine.com/medline/citation/2424237/Quantification_of_the_nail_fold_capillary_abnormalities_in_systemic_sclerosis_and_Raynaud's_syndrome_ L2 - http://www.diseaseinfosearch.org/result/2275 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.